<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高解释</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250319021627&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss<description>心血管高额外版：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250319021627&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期三，2025年3月19日06:16:29 +0000</lastbuilddate><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>配体诱导的泛素化释放了lag3免疫切解点功能，通过阻碍信号基序的膜隔离</title><link/>https://pubmed.ncbi.nlm.nih.gov/40101708/？ 08114047＆ff = 20250319021627＆v = 2.18.0.post9+e462414<description>淋巴细胞活化基因3（LAG3）已成为一个有望的癌症免疫疗法靶标，但是在这里，lag3激活的基础机制仍然难以捉摸。兼容复合物II类（MHC II类）和膜结合（但不是... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 3月6<b>日</b>。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">淋巴细胞活化基因3（LAG3）已成为一个有望的癌症免疫疗法靶标，但是在这里，lag3激活的基础机制仍然难以捉摸。兼容复合物II类（MHC II类和膜结合（但不是固体）纤维蛋白原样蛋白1（FGL1）。 lag3泛素化对于lag3介导的抗肿瘤免疫的抑制至关重要lag3治疗性抗体始终如一地反映了lag3的泛素化，其检查点阻断效果，患者同伴分析表明，lag3/cbl共表达可以用作生物标志物，以响应我们的研究范围。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40101708/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40101708</a> <a href=https://doi.org/10.1016/j.cell.2025.02.014>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40101708</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator>阳江</dc:creator><dc:creator>Anran Dai</dc:creator><dc:creator> Yuwei Huang</dc:creator><dc:creator>李</dc:creator><dc:creator>Jian Cui</dc:creator><dc:creator> Haochen Yang</dc:creator><dc:creator> lu si</dc:creator><dc:creator>陶</dc:creator><dc:creator>Zhengxu Ren</dc:creator><dc:creator> Ziwei Zhang</dc:creator><dc:creator> Si Mou</dc:creator><dc:creator>亨格鲁伊朱</dc:creator><dc:creator>Wenhui Guo</dc:creator><dc:creator> Qiang Huang</dc:creator><dc:creator> Yilin li</dc:creator><dc:creator>曼曼Xue</dc:creator><dc:creator> Jingwei Jiang</dc:creator><dc:creator> Fei Wang</dc:creator><dc:creator>李</dc:creator><dc:creator>Qiny Zhong</dc:creator><dc:creator> Kun Wang</dc:creator><dc:creator> Baichuan Liu</dc:creator><dc:creator>王王</dc:creator><dc:creator>高芬迷</dc:creator><dc:creator>Jun Guo</dc:creator><dc:creator> Liang Chen</dc:creator><dc:creator>克雷格·J·工人</dc:creator><dc:creator>Zhirong神</dc:creator><dc:creator>Yan Kong</dc:creator><dc:creator>达里奥·瓦尼亚利（Dario aa Vignali）</dc:creator><dc:creator> Chenqi Xu</dc:creator><dc:creator> Haopeng Wang</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>细胞</dc:source><dc:title>配体诱导的泛素化释放了lag3免疫切解点功能，通过阻碍信号基序的膜隔离</dc:title><dc:identifier>PMID：40101708</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.02.014</dc:identifier></item><item><title>心室射频导管消融后左心房内血肿</title><link/>https://pubmed.ncbi.nlm.nih.gov/40101156/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319021627&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur J Cardiovasc成像。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID <a href=https://doi.org/10.1093/ehjci/jeaf091>：</a> <a href="https://pubmed.ncbi.nlm.nih.gov/40101156/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40101156</a> |</p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40101156</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator>艾伦·迪尼兹·汉梅尔（Alan Diniz Hummel）</dc:creator><dc:creator>安德烈·瓦兹（AndréVaz）</dc:creator><dc:creator> AndréPacielloRomualdo</dc:creator><dc:creator>安德烈·斯克罗莫夫·德·阿尔伯克基</dc:creator><dc:date>2025-03-18</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心室射频导管消融后左心房内血肿</dc:title><dc:identifier>PMID：40101156</dc:identifier><dc:identifier> doi：10.1093/ehjci/jeaf091</dc:identifier></item><item><title>杂种与经皮的杂种与经皮的左心脏减压左心脏变体和完整或高度限制性的房间隔：多中心PICES研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/40100953/？ 08114047＆ff = 20250319021627＆v = 2.18.0.post9+e462414<description>结论：在HLH-sias的患者中，Hybrid LAD可以更快地创造房屋缺陷，与经皮LAD相比，具有更高的技术成功率，并且可能更少的程序性不良事件，以及支持同时的肺动脉症状，使我们的发现不良的肺动脉疗法的策略较高。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> CIRC CARDIOVASC INTERAL。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：具有完整或高度限制性的心房隔膜（HLH-ias）的新生儿需要立即进行产后干预才能生存。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对HLH-ias的所有新生儿进行了多中心回顾性分析，在2009年1月至2020年3月14日在北美先天性心脏计划中进行了生命的前36个小时。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在128例HLH-sias患者中，有105例（80％）接受了经皮LAD，23例（17％）混合动力have没有观察到诸如出生体重（3.1±0.6 vors 3.2±0.6 kg; <i>p</i> <i>=</i> 0.453）的杂质性特征的显着差异。 9对12.7±4.6毫米hg; <i>p</i> <i>=</i> 0.456），或最低的pH（7.13±0.14与7.09±0.15; <i>p</i> <i>=</i> 0.193）。 OUS LAD不成功，有7个需要转换为手术切除术的趋势是杂种LAD的严重不良事件（36％与17％； <i>P</i> = 0.141）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在HLH-sias的患者中，Hybrid LAD可以更快地创造房屋缺陷，与经皮LAD相比，具有更高的技术成功率，并且可能更少的程序性不良事件，以及支持同时的肺动脉症状，使我们的发现不良的肺动脉疗法的策略较高。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40100953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100953</a> <a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014243>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40100953</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Konstantin Averin</dc:creator><dc:creator>迈克尔·塞克勒（Michael D Seckeler）</dc:creator><dc:creator> Holly Bauser-Heaton</dc:creator><dc:creator> Matthew C Schwartz</dc:creator><dc:creator>保罗·坦道</dc:creator><dc:creator>卡梅隆·西曼（Cameron Seaman）</dc:creator><dc:creator>温迪·怀特塞德（Wendy Whiteside）</dc:creator><dc:creator>乔治·T·尼科尔森</dc:creator><dc:creator>Priti M Patel</dc:creator><dc:creator>布伦特·M·戈登（Brent M Gordon）</dc:creator><dc:creator>瑞安罗马人</dc:creator><dc:creator>Rajiv Devanagondi</dc:creator><dc:creator>凯莉·赫伯特</dc:creator><dc:creator>Sarosh P Batlivala</dc:creator><dc:creator> Brian Boe</dc:creator><dc:creator> Gurumurthy Hiremath</dc:creator><dc:creator> Jeffrey D Zampi</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>循环</dc:source><dc:title>杂种与经皮的杂种与经皮的左心脏减压左心脏变体和完整或高度限制性的房间隔：多中心PICES研究</dc:title><dc:identifier>PMID：40100953</dc:identifier><dc:identifier> doi：10.1161/CircInterventions.124.014243</dc:identifier></item><item><title> PCI用于手术无限符合的患者：另一部分拼图游戏</title><link/>https://pubmed.ncbi.nlm.nih.gov/40100952/？ 08114047＆ff = 20250319021627＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> CIRC CARDIOVASC INTERAL。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40100952/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100952</a> <a href=https://doi.org/10.1161/CIRCINTERVENTIONS.125.015200>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40100952</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator>蒂姆·金纳尔德（Tim Kinnaird）</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>循环</dc:source><dc:title>PCI用于手术无限符合的患者：另一部分拼图游戏</dc:title><dc:identifier>PMID：40100952</dc:identifier><dc:identifier> doi：10.1161/CircInterventions.125.015200</dc:identifier></item><item><title> MR机制的程序成功和MTEER的临床结果的时间变化：STS/TVT注册表的分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/40100951/？ 08114047＆ff = 20250319021627＆v = 2.18.0.post9+e462414<description>结论：除急性缺血MR以外，二尖瓣的经导管边缘对边缘维修的应用增加了，而技术成功的几率却更高，在现实情况下，与DMR相比，与DMR相比，急性缺血的死亡率相似。即。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> CIRC CARDIOVASC INTERAL。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：随着二尖瓣经导管边缘到边缘修复的适应症扩展到非平滑病因中，是否发生了技术成功和临床结果的变化，这是尚不清楚的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从2013年到2023年，分析了胸外科医生/美国心脏病学学院（STS/TVT）注册表。震惊的患者被排除在二尖瓣反流（MR）的机制中。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在过去的十年中，还包括68例患者，在过去的十年中，二尖瓣的边缘到边缘维修的应用已在功能上有很高的机制时间更多仅使用1个植入设备（在2022-2023期间为64.7％，而2013-2017期间的54.6％）在多变量分析中产生了负面<i>影响</i>，而对多变量分析产生了负面影响。与DMR相比，与DMR相比，与DMR相比，与DMR相比，1年的死亡率与DMR相比，MR机制和时间之间没有统计学意义的相互作用，这表明MR机制<i>对</i>技术和1年的临床效果没有统计学意义。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：除急性缺血MR以外，二尖瓣的经导管边缘对边缘维修的应用增加了，而技术成功的几率却更高，在现实情况下，与DMR相比，与DMR相比，急性缺血的死亡率相似。即。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40100951/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100951</a> <a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014819>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40100951</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Zach Rozenbaum</dc:creator><dc:creator> Sreekanth Vemulapalli</dc:creator><dc:creator> Miloni Shah</dc:creator><dc:creator> Andrzej Stanislaw Kosinski</dc:creator><dc:creator>埃里克·格纳尔（Eric Gnall）</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>循环</dc:source><dc:title>MR机制的程序成功和MTEER的临床结果的时间变化：STS/TVT注册表的分析</dc:title><dc:identifier>PMID：40100951</dc:identifier><dc:identifier> doi：10.1161/CircInterventions.124.014819</dc:identifier></item><item><title>旁路导管和早期技术失败对慢性肢体威胁性缺血的血运重建的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/40100950/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319021627&amp;v=2.18.0.post9+e462414<description>结论：对最佳CLI试验的经过治疗的结果的分析表明，在被认为适合开放手术旁路的CLTI患者中，SSGSV与SSGSV的临床超级性相关性。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> CIRC CARDIOVASC INTERAL。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：慢性肢体威胁性缺血（CLTI）的下肢血运重建的最佳策略（手术旁路与血管内干预）尚不清楚。基督旁路或内托治疗。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This was a planned as-treated analysis of the multicenter BEST-CLI (Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia) randomized controlled trial comparing open surgical bypass and ENDO for CLTI due to infrainguinal peripheral artery disease. Outcomes were tabulated based on the initial revascularization received: SSGSV ​​bypass, AC bypass, and ENDO. Analyses were performed for all治疗的患者不包括早期技术失败的人。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在1780例CLTI患者中，接受的治疗包括SSGSV旁路（n = 621），AC旁路（n = 236）和Endo（n = 923）程序，在30天死亡率中没有显着差异，主要的不良心血管事件发生了重大的不良事件，或者在30天内经历了30％的男性<i>。</i> &lt; <i>0.001</i> ）。 <i>.62</i> <i>]</i> ; CI， <i>p</i> &lt;0.001。在接受股骨血运重建的患者中，我们是最伟大的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：对最佳CLI试验的经过治疗的结果的分析表明，在被认为适合开放手术旁路的CLTI患者中，SSGSV与SSGSV的临床超级性相关性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：URL：https：//www.clinicaltrials.gov;</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40100950/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100950</a> <a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014716>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40100950</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator>迈克尔·孔戴（Michael S Conte）</dc:creator><dc:creator> Alik Farber</dc:creator><dc:creator>安德鲁·巴雷本（Andrew Barleben）</dc:creator><dc:creator> Emiliano Chisci</dc:creator><dc:creator> Gheorghe Doros</dc:creator><dc:creator> Vikram S Kashyap</dc:creator><dc:creator>艾哈迈德·凯西（Ahmed Kayssi）</dc:creator><dc:creator>菲利普·科尔（Philippe Kolh）</dc:creator><dc:creator>卡拉C莫雷拉</dc:creator><dc:creator>蒂莫西·尼普弗（Timothy Nypaver）</dc:creator><dc:creator>肯尼斯·罗森菲尔德（Kenneth Rosenfield）</dc:creator><dc:creator> Vincent L Rowe</dc:creator><dc:creator>安德烈斯·雪汗（Andres Schanzer）</dc:creator><dc:creator> Niten Singh</dc:creator><dc:creator> Jeffrey J Siracuse</dc:creator><dc:creator>迈克尔·B·斯特朗（Michael B Strong）</dc:creator><dc:creator>马修·梅纳德（Matthew T Menard）</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>循环</dc:source><dc:title>旁路导管和早期技术失败对慢性肢体威胁性缺血的血运重建的影响</dc:title><dc:identifier>PMID：40100950</dc:identifier><dc:identifier> doi：10.1161/CircInterventions.124.014716</dc:identifier></item><item><title>在退伍军人事务医疗系统中，PCI的特征和PCI的特征和结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/40100949/？ 08114047＆ff = 20250319021627＆v = 2.18.0.post9+e462414<description>结论：但是，PCI后长期死亡率的风险增加，但是在PCI之后，在手术上有资格的患者和不合格的患者进行了调整后的长期死亡风险增加。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Cardiovasc间隔。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：经皮冠状动脉干预后，手术血运重建的不可估量与死亡率增加有关（PCI）。在退伍军人事务医疗系统中，PCI在外科手术符合条件和不合格的患者中。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在2017年10月1日至2022年9月30日之间，患有左主和/或多发冠状动脉疾病的患者被鉴定出通过审查电子病历的综述确定的手术不合格的率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在调整后，总共有6192例患有左主和/或多发冠状动脉疾病（842个手术不合格和5350在手术上符合手术的符合条件）的患者，手术不合格与死亡率相关。 583-1600）随访期，尽管与复合MACE无关（时间比，0.859 [95％CI，0.685-1.078]）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：但是，PCI后长期死亡率的风险增加，但是在PCI之后，在手术上有资格的患者和不合格的患者进行了调整后的长期死亡风险增加。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40100949/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100949</a> <a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014899>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40100949</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator>克里斯托弗·P·科瓦奇（Christopher P Kovach）</dc:creator><dc:creator>杰里·利宾斯基（Jerry Lipinski）</dc:creator><dc:creator> Elise C Mesenbring</dc:creator><dc:creator>彼得·布洛斯（Peter Boulos）</dc:creator><dc:creator>艾比·普里比什（Abby Pribish）</dc:creator><dc:creator>迈克尔·索拉（Michael Sola）</dc:creator><dc:creator> Thomas J Glorioso</dc:creator><dc:creator>威廉·F·费顿</dc:creator><dc:creator>罗伯特·W·耶（Robert W Yeh）</dc:creator><dc:creator>斯蒂芬·沃尔多（Stephen W Waldo）</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>循环</dc:source><dc:title>在退伍军人事务医疗系统中，PCI的特征和PCI的特征和结果</dc:title><dc:identifier>PMID：40100949</dc:identifier><dc:identifier> doi：10.1161/CircInterventions.124.014899</dc:identifier></item><item><title>高出出血风险患者的血管内成像引导与血管造影引导的复合物PCI：对翻新复合PCI试验的次级分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/40100948/？ 08114047＆ff = 20250319021627＆v = 2.18.0.post9+e462414<description>结论：与没有HBR的患者相比，HBR的患者与患者相比，患有复杂PCI后心血管不良事件的风险增加。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> CIRC CARDIOVASC INTERAL。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：尽管高出出血风险（HBR）的患者经常患有复杂的冠状动脉病变，但尚不清楚血管内成像引导的经皮冠状动脉干预（PCI）是否会改善其预后。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这是对装修复合PCI试验的次要分析（血管内成像指南的随机对照试验与复杂经皮冠状动脉介入后对临床结果的临床结果的随机对照试验），其中在2022年5月202日，在韩国的20名患者中，有2021年在韩国的20名患者中招募了复杂的冠状动脉病变患者。随机接受血管内成像引导的PCI或血管造影引导的PCI，并根据HBR的存在进行分类。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在1639个试验人群中，有478名患者符合HBR标准。 <i>ED</i> ） HR，2.04 [95％CI，1.09-3.80]， <i>p</i> = 0.025），全因死亡（调整后的HR，3.30 [95％CI，1.93-5.62]； <i>p</i> &lt; <i>0.001</i> ），心脏死亡和心脏死亡两名HBR患者的血管造影引导PCI（9.7％对15.8％；调整后<i>的</i>HR，0.57 [95％CI，0.31-1.02]和非HBR<i>患者</i>（6.9％对10.8％；调整后的HR，0.65 [95％CI，0.43-0.99]; <i>P</i> = 0.045） </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与没有HBR的患者相比，HBR的患者与患者相比，患有复杂PCI后心血管不良事件的风险增加。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：URL：https：//www.clinicaltrials.gov;</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40100948/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100948</a> <a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014952>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40100948</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Jinhwan Jo</dc:creator><dc:creator>唱了李</dc:creator><dc:creator>Woochan Kwon</dc:creator><dc:creator> Seung-jae Lee</dc:creator><dc:creator> Jong-Young Lee</dc:creator><dc:creator> Seung Hun Lee</dc:creator><dc:creator> Doosup Shin</dc:creator><dc:creator> Sang Min Kim</dc:creator><dc:creator> Kyeong Ho Yun</dc:creator><dc:creator> Jae Young Cho</dc:creator><dc:creator> Chan Joon Kim</dc:creator><dc:creator> hyo-suk ahn</dc:creator><dc:creator> Chang-Wook Nam</dc:creator><dc:creator> Hyuck-Jun Yoon</dc:creator><dc:creator> Yong Hwan公园</dc:creator><dc:creator>王李</dc:creator><dc:creator>Ki Hong Choi</dc:creator><dc:creator>跆拳道公园</dc:creator><dc:creator>钟阳</dc:creator><dc:creator>Seung-Hyuk Choi</dc:creator><dc:creator> Hyeon-Cheol Gwon</dc:creator><dc:creator>年轻的bin歌</dc:creator><dc:creator>Joo-Yong Hahn</dc:creator><dc:creator> Sang Yeub Lee</dc:creator><dc:creator> Joo Myung Lee</dc:creator><dc:creator>翻新复合PCI调查人员</dc:creator><dc:date>2025-03-18</dc:date><dc:source>循环</dc:source><dc:title>高出出血风险患者的血管内成像引导与血管造影引导的复合物PCI：对翻新复合PCI试验的次级分析</dc:title><dc:identifier>PMID：40100948</dc:identifier><dc:identifier> doi：10.1161/CircInterventions.124.014952</dc:identifier></item><item><title> LVEF≤35％的扩张心肌病的预后和风险分层：心脏MRI见解以获得更好的预后</title><link/>https://pubmed.ncbi.nlm.nih.gov/40100943/？ 08114047＆ff = 20250319021627＆v = 2.18.0.post9+e462414<description>结论：患有晚期增强的心肌病的患者≥7.5％的SCD事件的风险增加，可用于SCD的风险分层。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Cardiovasc Imaging。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：当前的指南建议在左心室射血分数（LVEF）≤35％的心肌病患者中，植入心脏扭曲器的主要预防因素猝死（SCD）。基于心脏磁共振成像，可为LVEF≤35％的心肌病患者提供。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：总共1272例患有LVEF≤35％的心肌病患者，这些患者接受了心脏磁共振成像，而这本研究的主要终点是SCD或中止的SCD综合点，第二个终点是心力衰竭死亡和心脏失败的综合点。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在调整后的分析中，有101名患者<i>的</i>中值随访，101名患者达到了主要终点。 iuretic肽）（HR，2.02 [95％CI，1.18-3.44] <i>;</i> <i>P</i> = 0.01），LVEF（每5％HR，0.79 [95％CI，0.66-0.95]; <i>P</i> = 0.01 <sup>）</sup> ，晚期增强量为7.5％（HR，4.11 [95％CI，2.72-6.21]; <i>P</i> &lt;0.001; <i>P &lt;0.001）均与SCD或Abort scd相关。 ARY终点（调整后的HR，1.65 [95％CI，1.13-2.40]； P</i> = 0.009）由于高级诊所的增强症&lt;7.5％，患有晚期增强症的患者≥7.5％，LVEF≤20％的患者在竞争性COX分析中经历SCD事件的风险高7.12倍（年度事件率为4.8％）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：患有晚期增强的心肌病的患者≥7.5％的SCD事件的风险增加，可用于SCD的风险分层。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40100943/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100943</a> <a href=https://doi.org/10.1161/CIRCIMAGING.124.017246>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40100943</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator> di Zhou</dc:creator><dc:creator> Leyi Zhu</dc:creator><dc:creator> Shuang Li</dc:creator><dc:creator> Weichun Wu</dc:creator><dc:creator> Baiyan Zhuang</dc:creator><dc:creator> Jing Xu</dc:creator><dc:creator>杨阳</dc:creator><dc:creator>简他</dc:creator><dc:creator>王</dc:creator><dc:creator>Yuhui Zhang</dc:creator><dc:creator>刘关</dc:creator><dc:creator>小氧蛋白太阳</dc:creator><dc:creator>张张</dc:creator><dc:creator>宗佐顿</dc:creator><dc:creator>Arlene Sirajuddin</dc:creator><dc:creator>安德鲁·阿莱（Andrew E Arai）</dc:creator><dc:creator> Shihua Zhao</dc:creator><dc:creator> Minjie Lu</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>循环</dc:source><dc:title>LVEF≤35％的扩张心肌病的预后和风险分层：心脏MRI见解以获得更好的预后</dc:title><dc:identifier>PMID：40100943</dc:identifier><dc:identifier> doi：10.1161/cimimaging.124.017246</dc:identifier></item><item><title>我们可以在扩张心肌病的精确风险分层中迈出下一步吗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/40100942/？ 08114047＆ff = 20250319021627＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Cardiovasc Imaging。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40100942/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100942</a> <a href=https://doi.org/10.1161/CIRCIMAGING.125.018057>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40100942</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Viren Ahluwalia</dc:creator><dc:creator> Brian P Halliday</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>循环</dc:source><dc:title>我们可以在扩张心肌病的精确风险分层中迈出下一步吗？</dc:title><dc:identifier> PMID：40100942</dc:identifier><dc:identifier> doi：10.1161/cimimaging.125.018057</dc:identifier></item><item><title>心源性休克后认知功能和患者报告的结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/40100175/？ 08114047＆ff = 20250319021627＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAM Coll Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40100175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100175</a> <a href=https://doi.org/10.1016/j.jacc.2025.02.023>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40100175</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator>埃里克·J霍尔</dc:creator><dc:creator>杰夫·沙弗特</dc:creator><dc:creator>Sachin Agarwal</dc:creator><dc:creator> Colby R Ayers</dc:creator><dc:creator>亚历山德拉诉赛克斯</dc:creator><dc:creator>劳拉·H·拉克里茨（Laura H Lacritz）</dc:creator><dc:creator> Amil M Shah</dc:creator><dc:creator> E Wesley Ely</dc:creator><dc:creator> C Munro Cullum</dc:creator><dc:creator> Maryjane A Farr</dc:creator><dc:creator>詹姆斯·德·莱莫斯</dc:creator><dc:date>2025-03-18</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>心源性休克后认知功能和患者报告的结果</dc:title><dc:identifier>PMID：40100175</dc:identifier><dc:identifier> doi：10.1016/j.jacc.2025.02.023</dc:identifier></item><item><title> 2025年简洁临床指导：关于心源性冲击评估和管理的ACC专家共识声明：美国心脏病学院解决方案套装监督委员会的报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/40100174/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319021627&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J AM Coll Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40100174/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100174</a> <a href=https://doi.org/10.1016/j.jacc.2025.02.018>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40100174</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Shashank S Sinha</dc:creator><dc:creator>大卫明天</dc:creator><dc:creator>Navin K Kapur</dc:creator><dc:creator> Rachna Kataria</dc:creator><dc:creator>罗伯特·罗斯威尔</dc:creator><dc:date>2025-03-18</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>2025年简洁临床指导：关于心源性冲击评估和管理的ACC专家共识声明：美国心脏病学院解决方案套装监督委员会的报告</dc:title><dc:identifier>PMID：40100174</dc:identifier><dc:identifier> doi：10.1016/j.jacc.2025.02.018</dc:identifier></item><item><title>由急性心肌违规引起的心脏病性休克：全州注册表中揭示的无形挑战</title><link/>https://pubmed.ncbi.nlm.nih.gov/40100173/？ 08114047＆ff = 20250319021627＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J AM Coll Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40100173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100173</a> <a href=https://doi.org/10.1016/j.jacc.2025.02.027>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40100173</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator>埃里克·帕蒂（Eric P Cantey）</dc:creator><dc:creator>亚伦·洛帕辛斯基（Aaron Lopacinski）</dc:creator><dc:creator>米兰·塞思</dc:creator><dc:creator>戴维·汉密尔顿（David E Hamilton）</dc:creator><dc:creator> Elias J Dayub</dc:creator><dc:creator> Siddharth Gandhi</dc:creator><dc:creator> mir b basir</dc:creator><dc:creator>阿米尔·卡基（Amir Kaki）</dc:creator><dc:creator>瑞安·德·麦德（Ryan D Madder）</dc:creator><dc:creator> Devraj Sukul</dc:creator><dc:creator> Hitinder S Gurm</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>由急性心肌违规引起的心脏病性休克：全州注册表中揭示的无形挑战</dc:title><dc:identifier>PMID：40100173</dc:identifier><dc:identifier> doi：10.1016/j.jacc.2025.02.027</dc:identifier></item><item><title>呼吸综合病毒和心血管事件的起步：全国自制病例分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/40100172/？ 08114047＆ff = 20250319021627＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J AM Coll Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40100172/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100172</a> <a href=https://doi.org/10.1016/j.jacc.2025.02.031>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40100172</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator>垫子CHøjbjergLassen</dc:creator><dc:creator>丹尼尔·莫丁</dc:creator><dc:creator>尼克拉斯·迪比·约翰森（Niklas Dyrby Johansen）</dc:creator><dc:creator> Pradeesh Sivapalan</dc:creator><dc:creator>安德斯·赫维德（Anders Hviid）</dc:creator><dc:creator>泰拉·格罗夫·克劳斯（Tyra Grove Krause）</dc:creator><dc:creator>詹斯·乌里克·斯塔尔·詹森</dc:creator><dc:creator>Tor Biering-Sørensen</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>Respiratory Syncytial Virus and Incidence of Cardiovascular Events: A Nationwide Self-Controlled Case Series Analysis</dc:title><dc:identifier> pmid:40100172</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2025.02.031</dc:identifier></item><item><title> Best Practices for Transforming Cardiovascular Care Delivery and Implementation: A Modern Framework</title><link/> https://pubmed.ncbi.nlm.nih.gov/40100171/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319021627&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2025 Mar 10:S0735-1097(25)00468-1. doi: 10.1016/j.jacc.2025.02.020. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40100171/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100171</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2025.02.020>10.1016/j.jacc.2025.02.020</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40100171</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Ami B Bhatt</dc:creator><dc:creator> Ginger K Biesbrock</dc:creator><dc:creator> Cathleen Biga</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>Best Practices for Transforming Cardiovascular Care Delivery and Implementation: A Modern Framework</dc:title><dc:identifier> pmid:40100171</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2025.02.020</dc:identifier></item><item><title> Systolic Blood Pressure and Cardiovascular Mortality in US Adults Aged 80+ Taking Antihypertensive Medications</title><link/> https://pubmed.ncbi.nlm.nih.gov/40100170/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319021627&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2025 Feb 26:S0735-1097(25)00335-3. doi: 10.1016/j.jacc.2025.01.033. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40100170/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40100170</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2025.01.033>10.1016/j.jacc.2025.01.033</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40100170</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Huanhuan Yang</dc:creator><dc:creator> Chenxi Huang</dc:creator><dc:creator> Mitsuaki Sawano</dc:creator><dc:creator> Jeph Herrin</dc:creator><dc:creator> Guochong Chen</dc:creator><dc:creator> Zhihui Li</dc:creator><dc:creator> Erica S Spatz</dc:creator><dc:creator> Harlan M Krumholz</dc:creator><dc:creator> Yuan Lu</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>Systolic Blood Pressure and Cardiovascular Mortality in US Adults Aged 80+ Taking Antihypertensive Medications</dc:title><dc:identifier> pmid:40100170</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2025.01.033</dc:identifier></item><item><title> Use of Cardiac Rehabilitation in Older Patients with Myocardial Infarction Complicated by Cardiogenic Shock</title><link/> https://pubmed.ncbi.nlm.nih.gov/40099778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319021627&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2025 Mar 12:S0735-1097(25)05893-0. doi: 10.1016/j.jacc.2025.03.497. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40099778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40099778</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2025.03.497>10.1016/j.jacc.2025.03.497</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40099778</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Mohammed Essa</dc:creator><dc:creator> Sérgio RR Decker</dc:creator><dc:creator> Lichen Liang</dc:creator><dc:creator> Yang Song</dc:creator><dc:creator> Merilyn S Varghese</dc:creator><dc:creator> Jose F Figueroa</dc:creator><dc:creator> Laurence Sperling</dc:creator><dc:creator> Gregg C Fonarow</dc:creator><dc:creator> Steven J Keteyian</dc:creator><dc:creator> Michael P Thompson</dc:creator><dc:creator> Alexis Beatty</dc:creator><dc:creator> Dhruv S Kazi</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>Use of Cardiac Rehabilitation in Older Patients with Myocardial Infarction Complicated by Cardiogenic Shock</dc:title><dc:identifier> pmid:40099778</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2025.03.497</dc:identifier></item><item><title> Effect of Targeting apoC-III with Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia</title><link/> https://pubmed.ncbi.nlm.nih.gov/40099777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319021627&amp;v=2.18.0.post9+e462414<description> CONCLUSION: Plozasiran induced reductions in apoC-III and showed potentially favorable quantitative and qualitative changes in lipoproteins as assessed by NMR in patients with hypertriglyceridemia and mixed hyperlipidemia. Plozasiran reduced TRL-P by ∼50%, shifted LDL to larger particles, and modestly increased HDL-P concentration. While high-potency TRL-lowering therapies can lead to an overall LDL-C increase, plozasiran did not increase LDL-P or apoB but shifted LDL particle size distribution... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2025 Mar 12:S0735-1097(25)05892-9. doi: 10.1016/j.jacc.2025.03.496. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Plozasiran, an investigational siRNA targeting hepatic apoC-III, reduces triglyceride-rich lipoproteins (TRLs). The impact of plozasiran on lipoprotein particle numbers and sizes is unknown. However, reductions in the number of TRL particles (TRL-P) and a shift to possibly less atherogenic large low-density lipoprotein particles (LDL-P) are expected. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: To determine the impact of plozasiran on lipoprotein particle concentration and subclass distribution using nuclear magnetic resonance (NMR) in two phase 2 studies. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Patients (N=403) from SHASTA-2 (severe hypertriglyceridemia) and MUIR (mixed hyperlipidemia) were administered 2 total subcutaneous doses of plozasiran (10, 25, or 50 mg) or placebo at baseline and week 12. Comprehensive lipoprotein profiling was conducted with NMR. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: In SHASTA-2, there was a dose-dependent reduction in TRL-P, with placebo-adjusted total TRL-P reductions of -46% and reductions across all TRL subclasses with plozasiran. While total LDL-P was unchanged, large LDL-P concentration increased by +53% and medium by +56%; small LDL-P trended lower (-13%). Total HDL-P increased by +8%, primarily driven by a +36% increase in large high-density lipoprotein particles (HDL-P). Similarly, in MUIR, there were dose-dependent reductions in TRL-P, with total TRL-P significantly reduced by -48% (pooled plozasiran) and reductions across all TRL subclasses with plozasiran. While total LDL-P was unchanged, large and medium LDL-P levels increased by +88% and +46%, respectively; small LDL-P levels decreased by -28%. Total HDL-P increased by +12%, driven by a +83% increase in large HDL-P. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: Plozasiran induced reductions in apoC-III and showed potentially favorable quantitative and qualitative changes in lipoproteins as assessed by NMR in patients with hypertriglyceridemia and mixed hyperlipidemia. Plozasiran reduced TRL-P by ∼50%, shifted LDL to larger particles, and modestly increased HDL-P concentration. While high-potency TRL-lowering therapies can lead to an overall LDL-C increase, plozasiran did not increase LDL-P or apoB but shifted LDL particle size distribution from small dense LDL towards larger sizes. The ∼50% reduction in TRL-P with no increase in apoB and possibly beneficial qualitative changes in LDL suggests the potential of plozasiran to lower cardiovascular risk, which may be evaluated in a prospective outcomes trial.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40099777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40099777</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2025.03.496>10.1016/j.jacc.2025.03.496</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40099777</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Christie M Ballantyne</dc:creator><dc:creator> Daniel Gaudet</dc:creator><dc:creator> Robert S Rosenson</dc:creator><dc:creator> Robert A Hegele</dc:creator><dc:creator> Rong Zhou</dc:creator><dc:creator> Stacey Melquist</dc:creator><dc:creator> Jennifer Hellawell</dc:creator><dc:creator> Nicholas J Leeper</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>Effect of Targeting apoC-III with Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia</dc:title><dc:identifier> pmid:40099777</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2025.03.496</dc:identifier></item><item><title> Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy</title><link/> https://pubmed.ncbi.nlm.nih.gov/40099776/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319021627&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: Vutrisiran demonstrated evidence of benefit across the range of baseline disease severities in HELIOS-B, with the greatest benefit in earlier, less severe disease. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2025 Mar 11:S0735-1097(25)05823-1. doi: 10.1016/j.jacc.2025.03.477. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Vutrisiran reduced the risk of all-cause mortality (ACM) and recurrent cardiovascular (CV) events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in HELIOS-B (NCT04153149). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: To assess the effect of vutrisiran in HELIOS-B patients with different heart failure severities. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: HELIOS-B randomized ATTR-CM patients with NYHA class I-III (class IV or class III with National Amyloidosis Centre [NAC] stage III were excluded) 1:1 to vutrisiran 25 mg or placebo every 3 months for up to 36 months. This exploratory subgroup analysis assessed the primary composite endpoint of ACM and recurrent CV events, ACM, and additional functional and biomarker endpoints. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Of 654 patients, 84 (13%), 508 (78%), and 62 (9%) were in NYHA class I, II, and III, respectively. Median baseline NT-proBNP level was 1,920 ng/L. Lower risk of ACM and recurrent CV events was observed with vutrisiran versus placebo across baseline severity subgroups: Respective hazard ratios (95% CIs): 0.54 (0.27, 1.10), 0.77 (0.57, 1.03), and 0.68 (0.33, 1.41) in NYHA class I, II, and III,; 0.52 (0.30, 0.88), 0.61 (0.37, 1.00) and 0.93 (0.64, 1.35) in NT-proBNP tertiles (&lt;1,368 ng/L, ≥1,368 and &lt; 2,691 ng/L and ≥2,691 ng/L); 0.49 (0.34, 0.72) and 1.07 (0.74, 1.56) in NAC Stage I and II/III; and 0.69 (0.45, 1.07) and 0.74 (0.53, 1.02) in Columbia early and intermediate/late stage. Similar effects were observed in the monotherapy population (patients not on tafamidis at baseline) and across the additional endpoints evaluated. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Vutrisiran demonstrated evidence of benefit across the range of baseline disease severities in HELIOS-B, with the greatest benefit in earlier, less severe disease.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40099776/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40099776</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2025.03.477>10.1016/j.jacc.2025.03.477</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40099776</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Mathew S Maurer</dc:creator><dc:creator> Ronald M Witteles</dc:creator><dc:creator> Pablo Garcia-Pavia</dc:creator><dc:creator> Farooq H Sheikh</dc:creator><dc:creator> Caroline Morbach</dc:creator><dc:creator> Daniel Rodriguez Duque</dc:creator><dc:creator> Emre Aldinc</dc:creator><dc:creator> Satish A Eraly</dc:creator><dc:creator> Julian D Gillmore</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy</dc:title><dc:identifier> pmid:40099776</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2025.03.477</dc:identifier></item><item><title> More Than an Infant&#39;s Respiratory Illness: The Unfolding Cardiovascular Consequences of RSV in Older Adults</title><link/> https://pubmed.ncbi.nlm.nih.gov/40099775/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319021627&amp;v=2.18.0.post9+e462414<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2025 Mar 6:S0735-1097(25)05338-0. doi: 10.1016/j.jacc.2025.03.007. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40099775/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40099775</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2025.03.007>10.1016/j.jacc.2025.03.007</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40099775</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Pekka J Vartiainen</dc:creator><dc:creator>元黄</dc:creator><dc:creator>Mitsuaki Sawano</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>More Than an Infant&#39;s Respiratory Illness: The Unfolding Cardiovascular Consequences of RSV in Older Adults</dc:title><dc:identifier> pmid:40099775</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2025.03.007</dc:identifier></item><item><title> Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy</title><link/> https://pubmed.ncbi.nlm.nih.gov/40099774/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319021627&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: Vutrisiran maintained or improved functional capacity, health status, and QOL in more patients with ATTR-CM versus placebo over 30 months. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2025 Mar 8:S0735-1097(25)05796-1. doi: 10.1016/j.jacc.2025.03.454. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) progressively impairs functional capacity, health status, and quality of life (QOL). In HELIOS-B, vutrisiran reduced all-cause mortality and recurrent cardiovascular events compared with placebo in patients with ATTR-CM. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: To further analyze vutrisiran&#39;s efficacy on functional capacity, health status, and QOL. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Patients were randomized 1:1 to receive vutrisiran 25 mg or placebo every 12 weeks up to 36 months. 6-minute walk test (6-MWT) and Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) were completed at baseline and every 6 months. Cutoff values for worsening were a decrease from baseline of >;7 m, >;15 m, and >;35 m (6-MWT), and >;5 and >;10 points (KCCQ-OS). Additionally, change from baseline was analyzed in prespecified subgroups and KCCQ subdomains. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: In the overall population at Month 30, greater proportions of patients treated with vutrisiran versus placebo had maintained or improved 6-MWT distance according to all cutoffs analyzed (>;7 m [49.6% vs 33.2%], >;15 m [55.5% vs 38.6%], and >;35 m [68.4% vs 51.6%]; all P&lt;0.001). Similarly, greater proportions of patients experienced maintenance or improvement in KCCQ-OS according to cutoff values (>;5 points [63.5% vs 46.6%; P&lt;0.001], >;10 points [74.6% vs 60.7%; P&lt;0.01]). Additionally, least squares (LS) mean difference in change from baseline in KCCQ subdomains, and in 6-MWT and KCCQ-OS across prespecified subgroups, favored vutrisiran versus placebo. Benefits observed with vutrisiran were similar in the monotherapy population. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Vutrisiran maintained or improved functional capacity, health status, and QOL in more patients with ATTR-CM versus placebo over 30 months.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40099774/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319021627&v=2.18.0.post9+e462414">40099774</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2025.03.454>10.1016/j.jacc.2025.03.454</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40099774</guid><pubDate> Tue, 18 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Farooq H Sheikh</dc:creator><dc:creator> Gilbert Habib</dc:creator><dc:creator> WH Wilson Tang</dc:creator><dc:creator> Julian D Gillmore</dc:creator><dc:creator> Ugochukwu O Egolum</dc:creator><dc:creator> Simone Longhi</dc:creator><dc:creator> Chongshu Chen</dc:creator><dc:creator> Emre Aldinc</dc:creator><dc:creator> Marianna Fontana</dc:creator><dc:date> 2025-03-18</dc:date><dc:source>美国心脏病学院杂志</dc:source><dc:title>Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy</dc:title><dc:identifier> pmid:40099774</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2025.03.454</dc:identifier></item></channel></rss>